Ianalumab

Phase 3

NOVARTIS AG (NVSEF)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

NVSEFPhase 3$269.0B

ianalumab Phase 3 Est. Readout

Ianalumab• Primary Immune Thrombocytopenia (ITP)288

Q2 2027~QConfirmedSTALE

CT.gov

00%

Oct '26

NVSEFPhase 3$269.0B

ianalumab Phase 3 Est. Readout

Ianalumab• Primary Immune Thrombocytopenia (ITP)226

Oct 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Primary Immune Thrombocytopenia (ITP)

View Full Landscape

Drug Information

Target Indication

Primary Immune Thrombocytopenia (ITP)

Clinical Trial

NCT05653349

Last updated: 3/7/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

NVSEF

NOVARTIS AG

Biotechnology•North America•NASDAQ

Related Pipeline

FingolimodPhase 3

Multiple Sclerosis

dovitinibPhase 3

Solid Tumors

MF59-eH1N1_fPhase 3

Influenza

Glycopyrronium bromidePhase 3

Chronic Obstructive Pulmonary Disease

Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccinePhase 3

Swine-Origin Influenza A H1N1 Virus

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts